216102-94-2

Upstream product

• 216102-84-0 (3S,4S)-1,1-dibromo-3,4-(isopropylidenedioxy)octa-1,7-diene 
• 216102-98-6 (5S,6S)-5,6-(isopropylidenedioxy)oct-1-en-7-yne 
• 133337-02-7 ((4S,5S)-5-But-3-enyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol 
• 249603-83-6 (5S,6S)-5,6-(isopropylidenedioxy)-8-phenyloct-1-en-7-yne 

Downstream Products

• 216102-88-4 (5S,6S)-5,6-bis(tert-butyldimethylsiloxy)-8-phenyloct-1-en-7-yne 
• 249603-85-8 (5S,6S)-5,6-bis(tert-butyldimethylsilylenedioxy)-8-phenyloct-1-en-7-yne 

Relevant academic research and scientific papers

Stereocomplementary Construction of Optically Active Bicyclo[4.3.0]nonenone Derivatives

Treatment of (5S,6S)-5,6-bis(tert-butyldimethylsiloxy)-8-(substituted)oct-1-en-7-yne derivatives, prepared from diethyl L-tartrate, with Co2(CO)8 afforded the corresponding cobalt-complexed enynes, which were subsequently exposed to the typical Pauson-Khand conditions to furnish highly stereoselectively or exclusively (2S,3S,6S)-2,3-bis(tert-butyldimethylsiloxy)-9-(substituted)bicyclo-[4.3.0]non- 1(9)-en-8-ones. On the other hand, (3S,4S)-1-(substituted)oct-7-en-1-yne-3,4-diol congeners produced, on exposure to the Pauson-Khand conditions, (2S,3S,6A)-2,3-dihydroxy-9-(substituted)-bicyclo[4.3.0]-non-1(9)-en-8-one derivatives in a highly stereoselective manner. The newly developed procedure has been shown to be useful for construction of the 2,3-bis(oxygenated)-7-(substituted)-bicyclo[4.3.0]non-6-en-8-one framework in a stereocomplementary as well as stereoselective fashion.